The study of Aidi injection combined with PP chemotherapy in treating advanced non-smal cel lung cancer
Objective To compare the clinical ef ect,quality of life and toxicity between Aidi injection combined with PP regimen and PP regimen alone in treating advanced non-smal cel lung cancer (NSCLC)patients.Methods 56 advanced NSCLC patients were randomly divided into 2 groups with 28 cases in each group.Test group:paclitaxel 175mg/m2 ivgt d1 +cispla-tin 25mg/m2 ivgt d1 -3 combined with Aidi injection 100ml+5%GS 250ml ivgt d1 -14,Q3w.Control group:paclitaxel 175mg/m2 ivgt d1 +cisplatin 25mg/m2 ivgt d1 -3,Q3w.The clinical response was assessed after two cycles.The quality of life was assessed at baseline and after two cycles.Toxicity was assessed every cycle.Results The overal response(RR)rates were 35.71% and 28.57% in test group and control group (P>0.05)respectively.The disease control rates(DCR)were 78.57%and 53.57%in test group and control group (P<0.05)respec-tively.The quality of life of the test group was improved more significantly than that of the control group (P<0.05).The adverse reactions of test group,such as leukopenia,gastrointestinal adverse reactions and liver damage,were significantly reduced compared with control group (P<0.05).Conclusion Aidi injection which combined with PP regimen in treating advanced NSCLC could increase the disease control rate,improve the quality of life,and reduce the incidence of adverse reactions.
non-smal cel lung cancer(NSCLC)Aidi injectionpaclitaxelcisplatin
NETL
NSTL
万方数据
维普
